#1 Clinical Trials Search in Europe

Quemliclustat

This article explores the use of Quemliclustat, an innovative drug, in various clinical trials for cancer treatment. Quemliclustat, also known as AB680, is being studied in combination with other drugs and therapies to potentially enhance the body’s immune response against different types of cancer. These trials aim to evaluate the safety, efficacy, and potential benefits of Quemliclustat in treating advanced cancers, including pancreatic, prostate, and gastrointestinal malignancies.

Table of Contents

What is Quemliclustat?

Quemliclustat, also known as AB680, is an innovative drug currently being studied for its potential in treating various types of cancer[1]. It belongs to a class of medications called CD73 inhibitors, which are designed to boost the body’s immune response against cancer cells[2].

How Does Quemliclustat Work?

Quemliclustat works by blocking a protein called CD73. This protein is involved in producing a chemical called adenosine, which can suppress the immune system’s ability to fight cancer. By inhibiting CD73, quemliclustat aims to decrease the amount of adenosine in the tumor environment, potentially allowing the immune system to recognize and attack cancer cells more effectively[3].

What Conditions Does Quemliclustat Treat?

Quemliclustat is being investigated for the treatment of several types of cancer, including:

  • Biliary Tract Cancer: This includes cancers of the bile ducts and gallbladder[1].
  • Pancreatic Cancer: Specifically, metastatic pancreatic ductal adenocarcinoma (a type of pancreatic cancer that has spread to other parts of the body)[2].
  • Prostate Cancer: Particularly metastatic castrate-resistant prostate cancer (prostate cancer that has spread and no longer responds to hormone therapy)[4].
  • Upper Gastrointestinal Tract Cancers: Including cancers of the stomach, gastroesophageal junction, and esophagus[5].

Current Clinical Trials

Quemliclustat is currently being studied in several clinical trials to evaluate its safety and effectiveness. These trials are testing quemliclustat in different stages of cancer and in combination with other treatments. Some notable trials include:

  • A study combining quemliclustat with other drugs for biliary tract cancers[1].
  • A trial testing quemliclustat with chemotherapy for pancreatic cancer[2].
  • A study evaluating quemliclustat in combination with other immunotherapy drugs for prostate cancer[4].
  • A trial investigating quemliclustat with radiation therapy and other drugs for pancreatic cancer that may be surgically removable[6].

Combination Therapies

Quemliclustat is often studied in combination with other cancer treatments to potentially enhance its effectiveness. Common combinations include:

  • Chemotherapy: Quemliclustat is frequently combined with standard chemotherapy drugs like gemcitabine, cisplatin, or FOLFIRINOX (a combination of several chemotherapy drugs)[1][2].
  • Immunotherapy: It’s often paired with other immunotherapy drugs, particularly zimberelimab (also known as AB122), which is an anti-PD-1 antibody that helps the immune system recognize and attack cancer cells[4].
  • Radiation Therapy: Some studies are exploring the combination of quemliclustat with radiation treatment[6].

How is Quemliclustat Administered?

Quemliclustat is typically administered intravenously (through a vein). The dosing schedule can vary depending on the specific clinical trial and the combination of treatments being used. In many studies, it’s given every two weeks[1][3].

Potential Side Effects

As quemliclustat is still in clinical trials, the full range of potential side effects is not yet known. Researchers are carefully monitoring patients for any adverse reactions. The safety profile is being assessed in various studies, with a focus on identifying any severe side effects[1][2].

It’s important to note that quemliclustat is an experimental drug and is not yet approved for general use. Patients interested in this treatment should discuss clinical trial options with their healthcare providers.

Aspect Details
Drug Name Quemliclustat (AB680)
Mechanism of Action CD73 inhibitor, blocks adenosine production
Cancer Types Studied Pancreatic, Prostate, Biliary Tract, Gastrointestinal
Administration Intravenous (IV)
Combination Therapies Immunotherapy (e.g., Zimberelimab), Chemotherapy, Radiation
Key Outcomes Measured Safety, Efficacy, Progression-Free Survival, Overall Survival
Potential Benefits Enhanced immune response, Improved treatment effectiveness
Trial Phases Phase 1, 2, and 3 studies

FAQ

  • What is Quemliclustat? Quemliclustat, also known as AB680, is a drug that acts as a CD73 inhibitor. It works by blocking the production of adenosine, a chemical that can suppress the immune system's response to cancer.
  • What types of cancer are being studied with Quemliclustat? Quemliclustat is being studied in clinical trials for various types of cancer, including pancreatic ductal adenocarcinoma, prostate cancer, biliary tract cancers, and other gastrointestinal malignancies.
  • How is Quemliclustat administered? In the clinical trials, Quemliclustat is typically administered intravenously (IV) at specific intervals, such as every two weeks or as determined by the study protocol.
  • Is Quemliclustat used alone or in combination with other treatments? Quemliclustat is often studied in combination with other treatments, such as immunotherapy drugs (e.g., Zimberelimab), chemotherapy, and radiation therapy, to potentially enhance the overall effectiveness of cancer treatment.
  • What are the potential benefits of using Quemliclustat in cancer treatment? The potential benefits of Quemliclustat include enhancing the immune system's ability to recognize and attack cancer cells, improving the effectiveness of other cancer treatments, and potentially leading to better outcomes for patients with advanced cancers.

Ongoing Clinical Trials on Quemliclustat

  • Study on Quemliclustat and Chemotherapy for Patients with Metastatic Pancreatic Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +3

  • Study on the Safety and Effectiveness of Domvanalimab, Zimberelimab, and Quemliclustat in Adults with Advanced Upper Gastrointestinal Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Safety and Effectiveness of Etrumadenant, Quemliclustat, and Zimberelimab in Patients with Metastatic Colorectal Cancer

    Not recruiting

    1 1 1
    Investigated drugs:
    France Italy Spain

  • Study of Immunotherapy Combinations Including Zimberelimab for Patients With Advanced Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Poland Spain

Glossary

  • Quemliclustat: A drug that acts as a CD73 inhibitor, potentially enhancing the immune system's response against cancer by blocking the production of adenosine.
  • CD73: An enzyme that produces adenosine, which can suppress the immune system's response to cancer. Quemliclustat inhibits this enzyme.
  • Zimberelimab: An immunotherapy drug that targets the PD-1 protein, helping to activate the immune system against cancer cells.
  • FOLFIRINOX: A chemotherapy regimen consisting of multiple drugs (fluorouracil, leucovorin, irinotecan, and oxaliplatin) used to treat certain types of cancer.
  • Stereotactic Body Radiation Therapy (SBRT): A precise form of radiation therapy that delivers high doses of radiation to specific tumor sites.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the cancer progressing or worsening.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Adverse Events (AEs): Unfavorable and unintended signs, symptoms, or diseases associated with the use of a medical treatment.
  • Tumor Microenvironment (TME): The surrounding cellular environment in which the tumor exists, including blood vessels, immune cells, and signaling molecules.

References

  1. https://clinicaltrials.gov/study/NCT06048133
  2. https://clinicaltrials.gov/study/NCT06608927
  3. https://clinicaltrials.gov/study/NCT05688215
  4. https://clinicaltrials.gov/study/NCT04381832
  5. https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-domvanalimab-zimberelimab-and-quemliclustat-in-adults-with-advanced-upper-gastrointestinal-cancer/
  6. https://clinicaltrials.gov/study/NCT06048484